Pemziviptadil

普米肽地尔

Report date: 2022/07/19 20:00:45

Base Information

Drug NamePemziviptadil
Drug Alias NamePB-1046
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionVasoactive intestinal polypeptide receptor 2 agonists
TargetsVasoactive intestinal polypeptide receptor 2
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Cytokine Release SyndromeEssential Hypertension +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPhasebio Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPhasebio Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Cytokine Release SyndromeEssential Hypertension +[13] 

Other Information

ATC CodeN/A
Related LinksN/A